VEGF is one of the major factors that initiate and regulate angiogenesis (5) (6) (7) . VEGF promotes endothelial cell migration, proliferation, differentiation, and survival both in vitro and in vivo (2, 5, 6) , which are all critical for angiogenesis.
Serum response factor (SRF) was discovered in 1986 by Richard Treisman (8) who demonstrated that serum induces c-fos expression in fibroblasts through activation of a transcription factor, SRF, which binds to the serum response element (SRE) in the c-fos promoter. Since then, SRF has been shown in several types of cells (e.g., fibroblasts and muscle cells) to regulate expression of numerous genes the products of which are important for a variety of cellular activities (reviewed in ref 9) . SRF plays a critical role in embryogenesis and its inactivation in mouse embryos causes a mesoderm defect and results in embryonic lethality (10) . SRF knockout in mouse embryonic stem cells impairs expression of muscle specific genes and immediate early genes (11, 12) and alters cell adhesive properties (13) . The role of SRF in endothelial cell biology and angiogenesis has not been explored nor has the effect of VEGF on SRF expression or activation been investigated.
This study was aimed 1) to determine whether SRF is the mediator of VEGF-induced endothelial cell migration, proliferation, and angiogenesis; and 2) to explore whether and how VEGF regulates SRF expression and/or activation.
METHODS

Cell culture
Human umbilical vein endothelial cells (HUVEC) and rat gastric microvascular endothelial cells (RGMEC) were used as models to investigate the role of SRF in angiogenesis. HUVEC cells were purchased from the ATCC and maintained in culture in EBM-2 medium (Cambrex, Rockland, MA) supplemented with the EGM-2-MV Bulletkit. RGMEC cells were isolated from rat gastric tissue and maintained in culture as described in our previous study (14) . All in vitro experiments were done in both cell lines unless otherwise stated.
Oligonucleotide treatment
A 24-mer antisense oligonucelotide (5′-CGGCCCCAGCTTGGGTCGGTAACA-3′) corresponding to the sequence that includes the AUG translation initiation site of human SRF mRNA was designed to knock down SRF protein expression in endothelial cells. The complementary sense sequence (5′-TGTTACCGACCCAAGCTGGGGCCG-3′) was used as a control. Both oligonucleotides were phosphorothioated (Retrogen, San Diego, CA) and labeled with 6-carboxyfluorescein (6FAM) for detection. Serum-starved HUVEC and RGMEC cells (1x10 6 cells) were treated with 10 nmol of the oligonucleotide in serum-free medium and plated in 100 mm dishes. FBS was added to the cells 5 h later at a final concentration of 20%. Assays were conducted 48 h after the treatment.
Two-dimensional in vitro angiogenesis assay on Matrigel
Both HUVEC and RGMEC cells were seeded on growth factor-reduced Matrigels (BD Biosciences, Bedford, MA) in either the absence or presence of recombinant VEGF (human VEGF 165 for HUVEC and rat VEGF 164 for RGMEC; both were purchased from R&D System, Minneapolis, MN) at 50 ng/ml final concentration. Capillary-like structure formation was monitored over a 24 h period as described in our previous study (15) , photographed with a Nikon microscopic imaging system, and quantified by measuring the total length of connected cells in six random fields in each of four wells per treatment (n=24) and dividing this number by the total number of cells in the same field.
Three-dimensional in vitro angiogenesis assay in collagen gel matrix
Collagen gel matrices were prepared that contained 1.8 mg/ml type 1 rat tail collagen (BD Biosciences) and 3 µg/ml human Fibronectin (BD Biosciences) in a salt-balanced basal medium (pH 8.5) as described previously (16) . After the gel mixture (0.25 ml) was distributed into each well of a 24-well plate, the plate was allowed to sit for 10 min at room temperature and then was transferred into a tissue culture incubator for an additional hour until the gel was solidified. HUVEC cells were seeded on the gel at a density of 50,000 cells/well in growth medium and incubated for another hour until 90% of the cells were attached. Each well was washed with PBS to remove the unattached cells and then overlaid with another 0.25 ml collagen gel mixture on the top of the cells. After the second-layer of gel was solidified, the cells were washed with PBS again and cultured in fresh growth medium. Once the cells became confluent, they were washed thoroughly with PBS and then either maintained in a low serum medium (1%) or treated with VEGF at 50 ng/ml. Endothelial cell sprouting was monitored daily for 10 days and quantified by counting the number of connected sprouting cells in two focusing planes above and under the cobblestone monolayer in three random fields in each well of six wells per treatment (n=72).
In vitro endothelial cell migration assay
Both HUVEC and RGMEC cells were seeded in 6-well plates. When they became confluent, the cell monolayers were wounded with a razor blade as described in our previous study (17) and subsequently cultured in either the absence or presence of VEGF. Cell migration was monitored over a 48 h period and measured by counting the number of cells that had migrated into the denuded area and dividing this number by the area measured (cells/mm 2 ). For each treatment, cells were counted in three random-selected areas in each well of 12 wells (n=36).
G-/F-actin double staining in endothelial cells
Both HUVEC and RGMEC cells were seeded on collagen-coated microscopic slides. Once the cells became confluent, the cell monolayers were wounded with a sterile pipette tip (because a razor blade may damage the surface of the slide) and treated with either vehicle or VEGF for 15, 30 min, 1, 6, 12, 24, and 48 h. The cells were then fixed in 3.7% formaldehyde and permeabilized in cold acetone at -20°C. These cells were double-stained with Oregon Green 488-conjugated phalloidin and Texas red-conjugated DNase I (Molecular Probes, Eugene, OT) according to the protocol of the manufacturer. Images were captured with a Nikon microscopic imaging system. The relative contents of G-and F-actin were quantified using ImageQuant 5.0 software (Amersham Biosciences, Piscataway, NJ).
In vitro endothelial cell proliferation assay
Semiconfluent HUVEC and RGMEC cells in 24-well plates were cultured for 24 h in either the absence or presence of VEGF. Methyl-[ 3 H]thymidine was added into the culture 3 h before the experiment was terminated. The effect of SRF knockdown on cell proliferation was determined by measuring the radioactivity generated by the incorporated [ 3 H]thymidine, as described in our previous study (18) .
Effect of VEGF on SRF expression in endothelial cells
Serum-starved HUVEC and RGMEC cells were incubated with either vehicle or VEGF at 50 ng/ml for 15 and 30 min, 1, 2, 6, 12, and 24 h. Total RNA was isolated with TriZol reagent (Invitrogen, Carlsbad, CA), and protein was isolated in a cold lysis buffer (20 mM Tris-HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 300 mM NaCl, 0.2 mM sodium vanadate, 1% Triton X-100, 1% NP-40, protease inhibitor cocktail). SRF mRNA expression was examined by Northern hybridization with a 32 P-labeled SRF cDNA probe and normalized to 28S rRNA levels. SRF protein expression was examined by Western blotting with a specific antibody against SRF (Santa Cruz Biotechnology, Santa Cruz, CA) and normalized to β-actin levels. The expression signals were quantified with the ImageQuant 5.0 software.
SRF nuclear translocation in endothelial cells
Serum-deprived HUVEC and RGMEC cells were pretreated for 30 min with either vehicle or latrunculin B (0.5 µM; Calbiochem, San Diego, CA), an actin polymerization inhibitor, before treatment with vehicle or VEGF at 50 ng/ml for 30 and 60 min, fixed in 3.7% formaldehyde, and permeabilized in cold acetone. Endogenous peroxidase was blocked with 3% H 2 O 2 . The cells were incubated with the same anti-SRF antibody used for Western blotting for 2 h, probed with a streptavidin biotin system and then developed with AEC chromogen (DAKO, Carpinteria, CA).
Electrophoretic mobility shift assay (EMSA)
Serum-deprived HUVEC and RGMEC cells were pretreated for 30 min with either vehicle or latrunculin B before treatment with vehicle or VEGF at 50 ng/ml for 30 min. Protein was isolated from the cells and 10 µg protein were first incubated for 15 min with 1 µg polydI-dC in the binding buffer (20 mM HEPES, pH 7.9, 5 mM MgCl 2 , 100 mM KCl, 0.2 mM EDTA, and 20% glycerol) on ice to inhibit nonspecific binding. The mixture was subsequently incubated for an additional 15 min with 5 ng of either 32 P-labeled consensus SRE oligonucleotide (5′-GGATGTCCATATTAGGACATCT-3′) or 32 P-labeled mutant SRE oligonucleotide (5′-GGATGTCCATATTATTACATCT-3′) at room temperature. For super-shift assays, 2 µg of the anti-SRF antibody were also included into the reaction. To confirm specificity of the binding products, a 50-fold (=250 ng) excess of unlabeled consensus SRE oligonucleotide was added into the reaction to compete for SRF binding with the labeled SRE. The products were resolved on 5% native polyacrylamide gels. The gels were dried and exposed to a Kodak X-Omat film.
Signaling pathways for VEGF to induce SRF expression
Serum-deprived HUVEC and RGMEC cells were pretreated for 30 min with either vehicle or the MEK inhibitors, U0126 (20 µM) or PD98059 (20 µM) or for 60 min with either vehicle or the Rho inhibitor Clostridium difficile Toxin B (5 ng/ml; Calbiochem), or latrunculin B (0.5 µM). The cells were subsequently incubated with VEGF at 50 ng/ml for 30, 60, and 120 min. Protein extracts were analyzed by Western blotting with antibodies against the following proteins: SRF, phospho-ERK1/2, total-ERK1/2, and Rho A (Santa Cruz Biotechnology).
Induction of gastric ulcers in rats and assessment of in vivo angiogenesis
This part of the study was approved by the Subcommittee for Animal Studies of the Long Beach (California) Department of Veterans Affairs Medical Center. Gastric ulcers were induced in rats by local topical application of acetic acid as described in our previous study (19) . Immediately after ulcer induction, 100 µg plasmid DNA pcDNA3.1 (control) or pcDNA3.1 carrying SRF cDNA in the antisense orientation were injected into the submucosa around the site of ulcer induction as described in our previous gene therapy study with VEGF (20) . At 3, 7, and 14 days after injection, 12 rats from each group were killed to obtain gastric tissues for RNA, protein and histological assessment. In vivo angiogenesis in the ulcer granulation tissue was assessed by immunostaining with an antibody against the endothelial cell marker Factor VIII-related antigen (DAKO) and counting the number of stained microvessels in three microscopic fields per each slide under a x200 magnification (n =36).
Statistical analysis.
Numerical data are expressed as the means ± SD and analyzed by single classification ANOVA and significance among multiple comparisons was determined by Student's t test. P values <0.01 are considered as significant.
RESULTS
SRF is a critical requirement for VEGF-induced in vitro angiogenesis
To determine whether SRF is required for VEGF-induced angiogenesis, we introduced the SRF antisense oligonucleotide (labeled with the fluorescence dye 6FAM) into both HUVEC and RGMEC cells to knock down SRF protein expression. Cells treated with the complementary sense oligonucleotide were used as controls. Twenty-four hours after treatment, 95% of the HUVEC cells incorporated the oligonucleotides, as reflected by the presence of fluorescence signal in the cells. In the HUVEC cells treated with the SRF antisense oligonucleotides (aSRF), SRF protein levels were significantly reduced by 92 ± 6% (P<0.001) at 48 h after treatment (Fig.  1A) , compared with vehicle-treated HUVEC cells (control). There was no significant change in SRF protein levels between the HUVEC cells treated with the SRF sense oligonucleotides (sSRF) and the vehicle-treated cells, indicating that the SRF reduction was caused by the antisense oligonucleotide treatment rather than a general effect of exogenous DNA. A significant reduction (68±5%; P<0.001) in SRF protein expression was also obtained in aSRF RGMEC cells.
To examine the effect of SRF deficiency on in vitro angiogenesis, we first plated the oligonucleotide-treated and the vehicle-treated HUVEC and RGMEC cells on Matrigels and monitored them for 24 h in culture either with or without VEGF. In the presence of VEGF, the sSRF HUVEC cells formed capillary-like networks similar to the vehicle-treated HUVEC cells (control; Fig. 1B ). In the aSRF HUVEC cells, however, the network formation was reduced by 88 ± 3% (P<0.001; Fig. 1B and D) . It should be noted that both sSRF cells and control cells, but not the aSRF cells, also formed short and incomplete tube-like structures in the absence of VEGF. A similar reduction (84±5%) in capillary-like network formation was also obtained in aSRF RGMEC cells.
Interpretation of Matrigel assays can be problematic as they are two dimensional (2-D) and endothelial cells can form tube-like structures on the gel spontaneously without angiogenic stimulation. To overcome this limitation, we plated the aSRF, sSRF, and control HUVEC cells between two-layer sandwiched collagen gel matrices. After growth for 2 days, all the cells formed confluent cobblestone monolayers in between the two layers of collagen. At this time, the cells were cultured in maintenance medium (1% FBS) either lacking or containing VEGF (50 ng/ml). After incubation for 24 h, some of the control cells and sSRF cells cultured in the presence of VEGF migrated up and/or down into the gel matrices from the cobblestone monolayer and formed single-cell sprouts, whereas the aSRF cells did not (Fig. 1C) . After an additional 3 days of culture in the presence of VEGF, both the control and the sSRF cells migrated deeper into the collagen gel and formed complex networks, whereas majority of the aSRF cells remained resting as a cobblestone monolayer (Fig. 1C ). There were no sprouting cells found within gel matrices when the culture medium was not supplemented with VEGF. After 3-day VEGF treatment, the HUVEC cells with SRF knockdown had 95 ± 5% less cell sprouting than the control or sSRF cells (P<0.001; Fig. 1D ).
Taken together, these data indicate that SRF is a critical requirement for VEGF-induced in vitro angiogenesis.
SRF deficiency inhibits VEGF-stimulated endothelial cell migration
Since the aSRF cells failed to migrate and invade into collagen gel matrices in response to VEGF treatment and cell migration is an essential step for angiogenesis, we postulated that SRF deficiency might have impaired VEGF-induced in vitro angiogenesis by inhibiting endothelial cell migration. To test this hypothesis, we performed wounding assays by making standardized excisions in confluent RGMEC cell monolayers and measured the number of cells that migrated into the denuded area in response to VEGF. After incubation with VEGF for 48 h postwounding, the aSRF RGMEC cells had an over fourfold reduction in migration, compared with the control or the sSRF RGMEC cells (105±7 vs. 448±16 cells/mm 2 in control; P<0.001; Fig. 2A and C) .
Cell migration requires reorganization of cytoskeletal structures, particularly polymerization of G-actin to F-actin and the assembly of F-actin into stress fibers. Because actin is one of the SRFtargeted genes, we analyzed the effect of SRF deficiency on VEGF-induced actin dynamics by examining the relative content of G-and F-actin in HUVEC and RGMEC cells by double staining using Texas Red-conjugated DNase I to detect G-actin and Oregon Green-conjugated phalloidin to detect F-actin. After 30 min VEGF treatment, both the control HUVEC and RGMEC cells formed extensive F-actin stress fibers, while the aSRF cells failed to respond (Fig.  2B) . At 48 h, when migration assays were terminated, both the aSRF HUVEC and aSRF RGMEC cells still lacked appreciable F-actin stress fibers (Fig. 2B ). This result indicates that the inhibition of cell migration by SRF deficiency is likely related to insufficient actin polymerization and stress fiber formation.
SRF deficiency impairs VEGF-stimulated endothelial cell proliferation
Besides cell migration, VEGF also induces endothelial cell proliferation, which is another important component of angiogenesis. Since some of the SRF-targeted genes, such as c-fos (21) and egr-1 (22, 23) , are important for cell proliferation, we examined the effect of SRF deficiency on c-Fos and Egr-1 expression in response to VEGF treatment. Treatment for 2 h with VEGF significantly increased c-Fos and Egr-1 protein levels in the control RGMEC cells by 126.3 ± 14.5 and 129.5 ± 11.5% (both P<0.01), respectively. A similar induction was also found in the sSRF RGMEC cells but not in the SRF-deficient RGMEC cells (Fig. 2D) .
VEGF activates SRF expression in endothelial cells
Inhibition of VEGF-induced in vitro angiogenesis by knockdown of SRF suggests that SRF is a critical effector of the VEGF-induced angiogenic signaling in endothelial cells. To define the effect of VEGF on SRF, itself, we examined the dynamic expression of SRF mRNA and protein in both HUVEC and RGMEC cells after VEGF treatment for 15 and 30 min, 1, 2, 6, 12, and 24 h. In both types of cells, VEGF treatment significantly increased SRF mRNA expression. This induction started as early as 15 min after the treatment and persisted up to 2 h. A threefold maximal induction was reached at 1 h in both HUVEC and RGMEC cells (P<0.01; Fig. 3A ). VEGF treatment also significantly increased SRF protein expression with a peak induction (~7-fold) between 2 and 6 h (P<0.01; Fig. 3B ). These results clearly indicate that VEGF is a potent inducer of SRF mRNA and protein expression in endothelial cells.
To function as a transcription factor, SRF has to be translocated into the nucleus where it can bind to the SREs in the promoters of SRF-targeted genes. To determine the effect of VEGF on SRF subcellular translocation, we treated RGMEC cells with either vehicle or VEGF for 30 min and stained them with the anti-SRF antibody. In serum-starved, quiescent RGMEC cells, SRF was localized to both the cytoplasm and nucleus (Fig. 3C, left panel) . After VEGF treatment, SRF was predominantly localized to the nucleus (Fig. 3C , middle panel), indicating that VEGF triggers nuclear translocation of SRF.
To determine the effect of VEGF on SRF protein binding activity to SREs, we performed in vitro electrophoretic mobility shift assays using a synthetic SRE consensus oligonucleotide. Treatment with VEGF increased the binding activity of SRF to SRE (Fig. 3D, lane 3) , compared with controls (Fig. 3D, lane 2) . To ensure the specificity of the binding products, we performed supershift assays with the anti-SRF antibody (Fig. 3D , lanes 5 and 6), competition assays with a 50-fold excess of unlabeled SRE oligonucleotide (Fig. 3D, lanes 8 and 9) , and an assay with a mutant SRE sequence (Fig. 3D, lanes 11 and 12) . The retarded mobility of the binding complexes by the anti-SRF antibody, the disappearance of the binding complexes by treatment with unlabeled SRE, and the failure to form binding complexes with the mutant SRE together clearly demonstrate that the binding products are SRF-SRE specific.
Activation of SRF in endothelial cells by VEGF requires both MEK-ERK and Rho signaling
Since VEGF is a potent activator of the MEK-ERK pathway in endothelial cells (24, 25) and activation of this pathway induces SRF expression in other cells (26, 27) , we investigated whether the MEK-ERK pathway mediates VEGF-induced SRF expression in endothelial cells. We preincubated both HUVEC and RGMEC cells with the MEK specific inhibitors, U0126 or PD98059, and treated the cells subsequently with VEGF for 30, 60, and 120 min. U0126 pretreatment efficiently blocked ERK activation and completely inhibited the VEGF-induced increase in SRF protein expression in RGMEC cells (Fig. 4A) . Similar results were also obtained from HUVEC cells and with PD98059 treatment (data not shown). Thus activation of SRF expression by VEGF in endothelial cells requires MEK-ERK signaling.
It has been reported that VEGF-induced endothelial cell migration and angiogenesis require involvement of Rho family GTPases (28) (29) (30) and that Rho GTPases mediate SRF activation in fibroblasts through regulation of actin dynamics (31) (32) (33) . To determine whether VEGF-induced SRF expression in endothelial cells requires Rho GTPases, we pretreated both HUVEC and RGMEC cells with Clostridium difficile toxin B, a specific inhibitor for Rho GTPases, and then incubated the cells with VEGF. Treatment with toxin B completely inhibited VEGF-induced SRF protein expression in RGMEC cells (Fig. 4B) . Similar results were also obtained from HUVEC cells (data not shown), indicating that Rho GTPases are required for SRF induction in endothelial cells by VEGF.
Inhibition of actin polymerization blocks VEGF-induced SRF activation in endothelial cells and VEGF-induced in vitro angiogenesis
Recent studies indicate that Rho GTPase-mediated actin dynamics regulate SRF activation in fibroblasts through depletion of cellular G-actin pool (32, 33) . Since VEGF induces actin polymerization (34, 35) , which in turn leads to depletion of the G-actin pool, we examined whether VEGF activates SRF through a mechanism involving actin polymerization. We pretreated both HUVEC and RGMEC cells with the actin polymerization inhibitor latrunculin B and then incubated the cells with VEGF. latrunculin B completely inhibited VEGF-induced SRF expression in RGMEC cells (Fig. 4C) . The inhibition of actin polymerization by latrunculin B was confirmed by double fluorescence staining for G-actin and F-actin (Fig. 4D) . The strong correlation (r=0.87; P<0.01) between the ratio of F-actin to G-actin and SRF expression levels ( Fig. 4E) suggests that actin polymerization promotes SRF expression. Similar results were also obtained from HUVEC cells (data not shown). Latrunculin B pretreatment also inhibited VEGFinduced SRF nuclear translocation (Fig. 3C, right panel) and reduced SRF DNA binding activity (Fig. 3D, lanes 4, 7, 10 , and 13) in RGMEC cells. latrunculin B-treated RGMEC cells could not form tubular structures on Matrigel and also failed to form sprouts within collagen gel in response to VEGF (Fig. 4F) .
SRF deficiency inhibits angiogenesis in vivo
Angiogenesis is essential for wound and ulcer healing, because tissue regeneration requires restoration of the microvascular network to provide oxygen and nutrients to the healing site. To determine whether SRF is also important for angiogenesis in vivo in a physiologically/pathologically relevant condition, we induced experimental gastric ulcers in rats and locally injected the sites of induction with either a plasmid that expresses SRF antisense RNA or a nonexpressing plasmid as a control. SRF antisense RNA expression was detectable in the ulcer granulation tissue from days 3-7 after injection (Fig. 5A) . SRF protein levels in the ulcerated tissue of the aSRF rats were reduced by sevenfold (P < 0.01; Fig. 5B ). Local SRF deficiency in the ulcer area, as a result of SRF antisense RNA expression from the injected plasmid, led to a significant reduction in the number of regenerating microvessels in granulation tissue at the ulcer base (7±2/ mm 2 in the aSRF-treated rats compared with 32±5/mm 2 in control rats; P<0.01), reflecting inhibited angiogenesis (Fig. 5C) .
DISCUSSION
This study demonstrates for the first time that SRF is a critical requirement for VEGF-induced in vitro angiogenesis. VEGF is unable to induce SRF-deficient endothelial cells to form tubular structures on 2-D Matrigel or sprouts in three-dimensional (3-D) collagen gel. This defect is due to significant impairments in endothelial cell migration and proliferation likely resulting from inhibition of actin polymerization and suppression of immediate early gene expression. We also demonstrated that VEGF induces SRF expression and nuclear translocation and also increases SRF DNA binding activity in endothelial cells. The VEGF-induced SRF expression requires actin polymerization and MEK-ERK and Rho GTPase signaling, since blocking these pathways with specific inhibitors prevented VEGF-induced SRF expression.
Angiogenesis in vivo takes place in a 3-D macromolecular environment. During this process, angiogenic growth factors, such as VEGF, activate resting endothelial cells to migrate through dissolved basement membrane into the surrounding tissue where they form sprouts. It should be noted that cells might respond differently to the same stimulus when assayed within a 3-D collagen matrix as compared with a 2-D Matrigel, although the latter is still recognized as a useful tool to assess compounds that either stimulate or inhibit angiogenesis (36) .
VEGF stimulates endothelial cell migration by inducing actin polymerization to form actin stress fibers (34, 35) . Conversion of G-actin into F-actin leads to depletion of the G-actin pool. A new transcription factor, MAL (37), was recently discovered in NIH 3T3 cells to be a critical sensor of cellular G-actin levels (32, 33) . In quiescent NIH3T3 cells, MAL is predominantly localized to the cytoplasm where it is sequestered by G-actin. Upon cell stimulation by mitogens, G-actin dissociates from MAL and polymerizes into F-actin leading to G-actin pool depletion. As a result, liberated MAL translocates into nucleus where it forms an association with SRF to activate SRE-dependent genes, including SRF itself. Inhibition of G-actin polymerization by latrunculin B prevented VEGF-induced SRF expression, SRF nuclear translocation, SRF DNA binding activity, and in vitro angiogenesis, indicating that VEGF activates SRF, at least in part, by inducing actin polymerization that, in turn, results in depletion of the monomeric actin pool.
Besides actin, SRF also controls transcriptional activation of other cytoskeletal genes, such as myosin, vinculin, zyxin, talin, etc. (reviewed in ref 9) the products of which are also important for cell migration. Our study does not exclude the possibility that SRF deficiency in the endothelial cells might have impaired these cytoskeletal components as well.
The signaling pathways leading to VEGF-induced SRF expression, as examined in this study, are still not fully characterized. Our results indicate that both MEK-ERK and Rho-actin signaling are required for this induction. The SRF gene promoter contains both SRF and Sp1 binding sites, both of which are critical for SRF activation (38) . It has been reported that inhibition of the MEK-ERK pathway with U0126 in NIH3T3 cells resulted in a 50% reduction in SRF activation by serum, LPA, and platelet-derived growth factor (PDGF) and completely abolished SRF induction by phorbol 12-myristate 13-acetate (PMA; ref 26) . Serum-induced MAL nuclear accumulation is prevented by inactivation of Rho with toxin B and by inhibition of actin polymerization by latrunculin B but is not affected by inhibition of MEK-ERK with U0126 (32) . Inhibition of actin polymerization with latrunculin B also does not affect ERK phosphorylation (26) . Furthermore, we were unable to detect a significant effect on actin dynamics after treatment with the MEK inhibitors U0126 and PD98059 (our unpublished data). Strong evidence for crosstalk between these two pathways is currently lacking; however, it may be that the two pathways act in parallel in the regulation of VEGF-induced SRF expression/activation and that, although both pathways are necessary for this induction, neither pathway is itself sufficient. Further studies are necessary to clarify this issue. 
